Pathological and molecular assessment of sentinel lymph nodes in solid tumors

被引:22
作者
Krag, DN
Weaver, DL
机构
[1] Univ Vermont, Coll Med, Vermont Canc Ctr, Dept Surg, Burlington, VT 05405 USA
[2] Univ Vermont, Coll Med, Vermont Canc Ctr, Dept Pathol, Burlington, VT 05405 USA
关键词
D O I
10.1053/sonc.2002.32894
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Sentinel nodes (SNs) are the first set of nodes to receive drainage and cancer cells from a primary tumor. While there may be a single SN, frequently there are one to three or more SNs. The development of sentinel node surgery over the last decade has led to dramatic changes in the surgical approach to regional nodes draining solid tumors. The surgeon can now identify, to a level of accuracy previously impossible, the regional nodes most likely to be involved with cancer in any individual patient. This new capability comes at a cost; the principles guiding the extent of nodal surgery must be completely re-examined. The extent of surgical resection required to achieve each of the goals of regional node surgery-(1) establishing prognosis, (2) obtaining regional control, and (3) improving overall survival-may no longer be simply the default "regional node resection" and may vary depending on the clinical goals. Inseparable from this new surgical technology is the methodology employed for pathologic evaluation of SNs. It is critical that pathologists and clinicians conduct definitive clinical research directed toward defining the role and impact that SN surgery has on each of these surgical goals. Copyright 2002, Elsevier Science (USA). All rights reserved.
引用
收藏
页码:274 / 279
页数:6
相关论文
共 45 条
[31]   Sentinel node biopsy in ductal carcinoma in situ patients [J].
Pendas, S ;
Dauway, E ;
Giuliano, R ;
Ku, NN ;
Cox, CE ;
Reintgen, DS .
ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (01) :15-20
[32]  
SAPHIR O, 1948, CANCER, V1, P238, DOI 10.1002/1097-0142(194807)1:2<238::AID-CNCR2820010208>3.0.CO
[33]  
2-U
[34]   Microstaging of breast cancer patients using cytokeratin staining of the sentinel lymph node [J].
Schreiber, RH ;
Pendas, S ;
Ku, NN ;
Reintgen, DS ;
Shons, AR ;
Berman, C ;
Boulware, D ;
Cox, CE .
ANNALS OF SURGICAL ONCOLOGY, 1999, 6 (01) :95-101
[35]   Molecular staging of malignant melanoma - Correlation with clinical outcome [J].
Shivers, SC ;
Wang, XN ;
Li, WG ;
Joseph, E ;
Messina, J ;
Glass, LF ;
DeConti, R ;
Cruse, CW ;
Berman, C ;
Fenske, NA ;
Lyman, GH ;
Reintgen, DS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (16) :1410-1415
[36]   Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma - Discussion [J].
Fisher, B .
ANNALS OF SURGERY, 1997, 226 (03) :277-277
[37]  
Turner RR, 2000, CANCER-AM CANCER SOC, V89, P574, DOI 10.1002/1097-0142(20000801)89:3<574::AID-CNCR12>3.0.CO
[38]  
2-Y
[39]   Radioisotopic lymphatic mapping of the sentinel node in melanoma: Importance of immunohistochemistry [J].
Vaggelli, L ;
Castagnoli, A ;
Borgognoni, L ;
Urso, C ;
Matteini, M ;
Cesco, P .
TUMORI, 2000, 86 (04) :346-348
[40]   Sentinel node biopsies in melanoma patients: A protocol for accurate, efficient, and cost-effective analysis by preselection for immunohistochemistry on the basis of Tyr-PCR [J].
van der Velde-Zimmermann, D ;
Schipper, MI ;
de Weger, RA ;
Hennipman, A ;
Rinkes, IHMB .
ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (01) :51-54